Weight Loss Injections: What Retatrutide Is and Where Things Stand

Why people are searching for retatrutide in the first place

The honest answer is that the trial numbers turned heads. A phase 2 study published in the New England Journal of Medicine reported participants on the highest retatrutide dose losing around 24% of their body weight over 48 weeks, figures that sit above the headline results from any medicine currently on the UK market. That is genuinely interesting science. But a phase 2 trial involves a few hundred participants and is designed to test safety signals and find the right dose range, not to confirm effectiveness at scale. Phase 3 programmes involve thousands of people across multiple countries and take years. Retatrutide is currently in that phase 3 stage; no results have been published, no regulatory submission to the MHRA has been announced, and there is no approved product. What that means practically: if you are considering where to buy weight loss injections and you come across retatrutide for sale anywhere online right now, you are looking at an unlicensed substance with no verified supply chain, no UK clinical oversight and no legal route to a prescription. The MHRA's Yellow Card scheme exists precisely to report situations like this.

The triple-receptor mechanism: how retatrutide differs from what is licensed

To understand what retatrutide is trying to do, it helps to compare the mechanisms. Wegovy (semaglutide) activates a single receptor, GLP-1, which slows gastric emptying, reduces appetite and improves blood sugar regulation. Mounjaro (tirzepatide) adds a second, GIP, making it the only dual-receptor agonist licensed for weight management in the UK. Both are described in detail on the retatrutide and weight loss injection context page alongside this one. Retatrutide adds a third: glucagon, which raises metabolic rate and promotes fat breakdown. The theory is that combining all three pathways produces additive effects on energy balance. Early data support that hypothesis. Whether the long-term safety profile, the tolerability at higher doses and the breadth of eligible patients hold up in phase 3 will determine whether regulators ever see a submission, and our retatrutide weight loss injection page explains the current development timeline in more detail. A medicine that works brilliantly in 300 carefully selected participants and a medicine that works safely for hundreds of thousands of real-world patients are not the same thing. That gap is what clinical development is for.

Which injection is the right one for you right now

This is the decision the skeleton of this page is built around, so here it is plainly. You cannot choose retatrutide. It does not exist as a legal option in the UK, and that will remain true until (and unless) Eli Lilly completes phase 3, submits a dossier to the MHRA, and receives a marketing authorisation. That process typically takes several years from where things stand in mid-2026. What you can choose between, subject to clinical assessment, is Mounjaro or Wegovy, and our weight loss injection guide explains how each of these licensed medicines works, who they are suitable for, and what to expect from treatment. NICE recommended tirzepatide for NHS use in December 2024 (NICE TA1026), and the evidence base for both medicines now spans tens of thousands of patients across multiple trial programmes. Private eligibility for either medicine starts at a BMI of 30, or 27 with a weight-related condition such as hypertension, type 2 diabetes or obstructive sleep apnoea, a prescriber assesses the full picture, not just the number. If you want to see how these two medicines compare on results, side effects and dosing schedules, the overview of licensed weight-loss injections covers this in detail. For context on what treatment costs in the UK private market, that is covered on our weight-loss treatment page.

What a legitimate prescription journey looks like

Because retatrutide searches often come from people who are frustrated (with NHS waiting lists, with the pace of science, with feeling like the best option is always just out of reach) it is worth describing what a legitimate route to treatment actually looks like today. A clinician reads your consultation answers the same day. Not software: a GPhC-registered Independent Prescriber. If the medicine is clinically suitable, a prescription is issued. Your order is dispatched before the end of the working day if you submitted before noon, and DPD delivers it the next working day in plain, unmarked packaging, a box with no brand names on the outside and a pen inside that is exactly what was prescribed. That is the whole process, including the aftercare line if questions come up later. Our clinical team and prescribing standards are described on our about page, and you can verify our pharmacy on the GPhC register using premises number 9012878. When you are ready to see whether you are eligible for what is actually licensed, check your eligibility with a free consultation.